AU7927798A - Nutritional composition for subjects under stress - Google Patents
Nutritional composition for subjects under stress Download PDFInfo
- Publication number
- AU7927798A AU7927798A AU79277/98A AU7927798A AU7927798A AU 7927798 A AU7927798 A AU 7927798A AU 79277/98 A AU79277/98 A AU 79277/98A AU 7927798 A AU7927798 A AU 7927798A AU 7927798 A AU7927798 A AU 7927798A
- Authority
- AU
- Australia
- Prior art keywords
- composition
- carnitine
- stress
- alkanoyl
- ginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims description 18
- 235000016709 nutrition Nutrition 0.000 title description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 15
- 240000004371 Panax ginseng Species 0.000 claims description 11
- 235000008434 ginseng Nutrition 0.000 claims description 11
- 240000003444 Paullinia cupana Species 0.000 claims description 10
- 235000000556 Paullinia cupana Nutrition 0.000 claims description 10
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 9
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 9
- 240000000143 Turnera diffusa Species 0.000 claims description 9
- -1 alkanoyl L-carnitine Chemical compound 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 9
- 235000004952 turnera diffusa Nutrition 0.000 claims description 9
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 7
- 235000011090 malic acid Nutrition 0.000 claims description 7
- 239000001630 malic acid Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 6
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 6
- 244000068988 Glycine max Species 0.000 claims description 6
- 235000010469 Glycine max Nutrition 0.000 claims description 6
- 239000000787 lecithin Substances 0.000 claims description 6
- 229940067606 lecithin Drugs 0.000 claims description 6
- 235000010445 lecithin Nutrition 0.000 claims description 6
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 claims description 5
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 claims description 5
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 claims description 5
- 229960000317 yohimbine Drugs 0.000 claims description 5
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 4
- 201000001881 impotence Diseases 0.000 claims description 4
- 206010025482 malaise Diseases 0.000 claims description 4
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 3
- 241000682653 Corynanthe Species 0.000 claims description 2
- 235000002789 Panax ginseng Nutrition 0.000 claims description 2
- 235000008690 Pausinystalia yohimbe Nutrition 0.000 claims description 2
- 235000009206 Turnera diffusa Nutrition 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 206010003549 asthenia Diseases 0.000 claims description 2
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000005515 coenzyme Substances 0.000 claims description 2
- IGQBPDJNUXPEMT-SNVBAGLBSA-N isovaleryl-L-carnitine Chemical compound CC(C)CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IGQBPDJNUXPEMT-SNVBAGLBSA-N 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 150000002739 metals Chemical class 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 230000001107 psychogenic effect Effects 0.000 claims description 2
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000000419 plant extract Substances 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 239000002253 acid Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 230000001568 sexual effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 241000675108 Citrus tangerina Species 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229940071325 yohimbine 5 mg Drugs 0.000 description 3
- 108010011485 Aspartame Proteins 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 125000001589 carboacyl group Chemical group 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000036314 physical performance Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000036299 sexual function Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 230000003245 working effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
WO 99/03364 PCT/IB98/01056 NUTRITIONAL COMPOSITION FOR SUBJECTS UNDER STRESS 5 DESCRIPTION The present invention relates to a nutritional composition or medical food for subjects in a debilitated state as a result of stress. In the developed countries, stress syndrome afflicts a substantial number of people. The causes of the stress are multiple io and attributable mainly to living conditions in large and overcrowded urban areas and to the problems these give rise to such as traffic, noise and pollution. Another important cause consists in problems associated with working activity or economic worries. This syndrome afflicts all social classes, but mainly affects s15 people involved in the production cycle, who often, as a result, are subject to greater competitive stress stimuli both in the work environment and in the conduct of their social relations. Generally speaking, stress syndrome is not a debilitating "disease" to the extent that it makes people bed-ridden, but it is 20 certainly a frequent cause of people taking days off work. Since it afflicts a substantial number of individuals, it causes a considerable burden of economic damage to the entire community during the working year. Stress syndrome, which in the past was improperly called "nervous breakdown", is characterised, in the absence of 25 active disease, by concomitant states of malaise, such as a lack of strength, debilitation, states of mental and physical fatigue, lack of concentration and attention, and lack of sexual vigour and libido. There are no specific drugs for the treatment of stress. Temporary detachment from the causes of the stress, for instance by 30 spending a holiday in a pleasant locality and in a relaxing WO 99/03364 PCT/IB98/01056 2 environment, would certainly have a positive effect, facilitating recovery of mental and physical well-being with an improvement in physical performance and an increase in sexual vigour and libido. This, however, is not always possible for various reasons such 5 as, for example, work commitments, family demands and economic difficulties. A number of patients suffering from stress are treated with benzodiazepines or with drugs which are active in mood disorders. Benzodiazepines are used to alleviate symptoms such as anxiety or o10 irritability, but present the drawback of causing addiction as well as further depressing libido and sexual vigour, thus triggering a mechanism in male subjects of reproductive age which itself proves to be a cause of additional malaise. A number of substances which axre useful for the treatment of 15 sexual impotence of psychogenic or other origin are already well known. Equally well known are substances endowed with stimulant activity. For example, L-carnitine, when used for the treatment of patients undergoing regular dialysis treatment, also induces recovery of normal sexual function in such patients (De Felice SL, 20 Lyons P, Gaffar MC, Sheridan MJ, Dial-Transplant, 1996, vol/iss/pg. 25/6 368-373). Popular medicine (and belief) in oriental and South American countries (China, Brazil) have, since time immemorial, accredited the extracts of the roots, bark and leaves of various "exotic" plants 25 with multiple therapeutic and stimulant effects. Ginseng has been used in Chinese medicine for more than 2000 years for the treatment of sexual impotence and for other diseases. Also well known is the activity of yohimbine in improving sexual function; see, for example, "Clinical Studies in Impotence": K Reid et al., Lancet 2, 30 421-423 (1987). Guarana is used by Brazilian indigenous WO 99/03364 PCT/IB98/01056 3 populations for the preparation of a stimulating beverage (Pharmacognosy, Edward P Claus, Varro E Tyler, Lynn R Brady, 6th edition pp. 292-293). Damiana has also long been known to be endowed, according to popular belief, with stimulant activity (J s Psychoactive Drugs 16 (3): 267-268, 1984). The purpose of the present invention is now to provide a therapeutic medical food suitable for alleviating and treating states of malaise caused by stress and for promoting sexual vigour. The therapeutic medical food of the invention comprises the following i0 compounds in combination: 1) L-carnitine or an alkanoyl L-carnitine in which the linear or branched-chain alkanoyl has 2-8, and preferably 2-6, carbon atoms, or one of their pharnacologically acceptable salts; 2) ginseng (natural extract of Panax ginseng); 15 3) yohimbine (natural extract of Corynanthe yohimbe); 4) guarana (natural extract of Paullinia cupana); 5) damniana (natural extract of Turnera diffusa, var aphrodisiacc4; 6) lecithin of soya, and 7) malic acid. 20 The alkanoyl L-carnitine should preferably be chosen from among the group comprising acetyl, propionyl, butyryl, valeryl and isovaleryl L-carnitine or one of its pharmacologically acceptable salts. What is meant by pharmacologically acceptable salt of L 2s carnitine or of an alkanoyl L-carnitine is any salt of these with an acid which does not give rise to unwanted toxic or side effects. Such acids are well known to pharmacologists and experts in pharmacy. Non-limiting examples of pharmacologically acceptable salts of L-carnitine or of the alkanoyl L-carnitines are chloride, bromide, 30 orotate, acid aspartate, acid citrate, acid phosphate, fumarate and WO 99/03364 PCT/IB98/01056 4 acid fumarate, lactate, maleate and acid maleate, acid oxalate, acid sulphate, glucose phosphate, tartrate and acid tartrate. The components of the combination according to the invention, once combined, exhibit an unexpected potent synergistic effect 5 which brings about an improvement in physical performance and in the mental and physical condition of patients suffering from stress syndrome. Very important and surprising is the synergistic effect shown by the combination of ginseng, yohimbine and L-carnitine in restoring sexual vigour and libido. 10 The effect of the combination is, in fact, distinctly superior to the sum of the effects of the individual components. Of particular interest is the interaction between malic acid and L-carnitine. The complementary effect exerted by these two compounds on energy production via two different metabolic 15 pathways - malic acid via the Krebs cycle, and L-carnitine via 0 oxidation - stimulates the body to produce a large amount of energy, which is useful in enabling the individual to emerge from the state of fatigue, debilitation or asthenia caused by stress. The interaction between guarana and damiana also results in 20 an intense stimulatory effect, enabling most subjects presenting a state of torpor or lack of interest to emerge from these conditions. L-carnitine and lecithin of soya favour the metabolisation of fatty acids, exerting a hypolipaemic effect on the body, which, though having no direct repercussions in terms of improving stress 25 syndrome, is aimed at enhancing the individual's general state of health. The weight-to-weight ratio of L-carnitine or of an alkanoyl L carnitine to ginseng, yohimrnbine, guarana and damiana may vary over a broad range, This ratio should preferably range from WO 99/03364 PCT/IB98/01056 5 1:0.1:0.0025:0.1:0.1 to 1:10:0.25:100:100. One preferred ratio is 1:1:0.025:1:1. By way of non-limiting examples a number of sachet formulations according to the invention are given containing the s following components in combination: Composition 1 L-carnitine HC 200 mg Ginseng 200 mg Lecithin of soya 400 mg io Aspartamne 20 mg Sucrose 1500 mg Tangerine flavouring 100 mg Yohimbine 5 mg Malic acid 50 mg 15 Granular mannitol q.s. to 3000 mg Composition 2 L-carnitine HCI 200 mg Ginseng 200 mg Lecithin of soya 200 mg 20 Aspartame 20 mg Sucrose 1000 mg Tangerine flavouring 100 mg Yohimbine 5 mg Guarana 200 mg 25 Damiana 200 mg Malic acid 50 mg Granular mannitol q.s. to 3000 mg 30 WO 99/03364 PCT/IB98/01056 6 Composition 3 L-carnitine HC1 200 mg Ginseng 200 mg Lecithin of soya 200 mg 5 Aspartame 20 mg Sucrose 1000 mg Tangerine flavouring 100 mg Yohimbine 5 mg Guarana 500 mg I0 Damiana 500 mg Malic acid 50 mg Granular mannitol q.s. to 3000 mg The composition according to the invention may additionally contain vitamins, metals, coenzymes, inorganic or organic is antioxidants or their precursors.
Claims (9)
1. A medical food composition suitable for alleviating and treating states of malaise caused by stress, comprising the following in combination: 5 (a) L-carnitine or an alkanoyl L-carnitine in which the linear or branched-chain alkanoyl group has 2-8, and preferably 2-6 carbon atoms, or one of their pharmacologically acceptable salts; (b) a mixture of natural plant extracts; 10 (c) lecithin of soya; (d) malic acid.
2. The composition of claim 1, wherein the alkanoyl L-carnitine is selected from the group comprising acetyl, propionyl, butyryl, valeryl and isovaleryl L-carnitine or one of its is pharmacologically acceptable salts.
3. The composition of claim I, wherein the natural plant extracts are selected from the group comprising the natural extract of Corynanthe yohimbe or yohimbine, the natural extract of Panax ginseng or ginseng, the natural extract of Paullinia cupana or 20 guarana, and the natural extract of Turnera diffusa or damiana.
4. The composition of claim 3, wherein the weight-to-weight ratio of L-carnitine or of an alkanoyl L-carnitine to ginseng, yohimbine, guarana and damiana ranges from 25 1:0.1:0.0025:0.1:0.1 to 1:10:0.25:100:100.
5. The composition of claim 4, wherein said ratio is 1:1:0.025; 1:1.
6. The composition of the preceding claims, further comprising vitamins, metals, coenzymes, inorganic or organic antioxidants or their precursors. WO 99/03364 PCT/IB98/01056 8
7. The composition of any of the preceding claims for the treatment of stress-induced or psychogenic sexual impotence.
8. The composition of any of the preceding claims for the treatment of states of fatigue, lack of strength or asthenia 5 caused by stress.
9. The composition of any of the preceding claims, which presents itself in the form of a solid, semisolid, liquid, semiliquid, powder, grains, tablets, capsules, granules, or powder for oral use. 10
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT97RM000435A IT1293539B1 (en) | 1997-07-16 | 1997-07-16 | NUTRITIONAL COMPOSITION FOR SUBJECTS IN A STATE OF DEBILITATION CAUSED BY STRESS |
| ITRM97A000435 | 1997-07-16 | ||
| PCT/IB1998/001056 WO1999003364A1 (en) | 1997-07-16 | 1998-07-10 | Nutritional composition for subjects under stress |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU7927798A true AU7927798A (en) | 1999-02-10 |
| AU727448B2 AU727448B2 (en) | 2000-12-14 |
Family
ID=11405180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU79277/98A Ceased AU727448B2 (en) | 1997-07-16 | 1998-07-10 | Nutritional composition for subjects under stress |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0999757A1 (en) |
| JP (1) | JP2001510026A (en) |
| KR (1) | KR20010021694A (en) |
| CN (1) | CN1263439A (en) |
| AU (1) | AU727448B2 (en) |
| CA (1) | CA2296540A1 (en) |
| HU (1) | HUP0004526A3 (en) |
| IT (1) | IT1293539B1 (en) |
| PL (1) | PL338079A1 (en) |
| SK (1) | SK181999A3 (en) |
| WO (1) | WO1999003364A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT410277B (en) * | 2001-02-22 | 2003-03-25 | Peter Dr Frigo | DRINK |
| LV12978B (en) * | 2001-09-07 | 2003-05-20 | Ivars Kalvins | Pharmaceutical composition |
| ITRM20010708A1 (en) | 2001-12-04 | 2003-06-04 | Sigma Tau Ind Farmaceuti | USE OF AN ALCANOIL L-CARNITINE FOR THE TREATMENT OF ERECTILE DYSFUNCTION. |
| MXPA05003285A (en) * | 2002-09-28 | 2005-07-05 | Boehringer Ingelheim Int | Composition comprising panax ginseng and paullinia cupana extracts. |
| DE102005053241A1 (en) * | 2005-11-08 | 2007-05-16 | Schwabe Willmar Gmbh & Co | Extracts of the bark of Corynanthe species and their use, as well as pharmaceuticals containing them, dietetic foods and pharmaceutical preparations |
| US20100255127A1 (en) * | 2007-11-21 | 2010-10-07 | Kracie Pharma, Ltd. | Aromatase inhibitor |
| JP6446265B2 (en) * | 2014-12-26 | 2018-12-26 | 花王株式会社 | Solid composition |
| CN113116898A (en) * | 2021-04-20 | 2021-07-16 | 北京天玺宝科技有限公司 | Composition containing levocarnitine or acetyl levocarnitine and yohimbine with weight losing function and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5626849A (en) * | 1995-06-07 | 1997-05-06 | Reliv International, Inc. | Weight loss composition for burning and reducing synthesis of fats |
| FR2748659B1 (en) * | 1996-05-14 | 1998-07-24 | Lvmh Rech | TOPICAL SLIMMING COMPOSITION |
| US5744187A (en) * | 1996-12-16 | 1998-04-28 | Gaynor; Mitchel L. | Nutritional powder composition |
-
1997
- 1997-07-16 IT IT97RM000435A patent/IT1293539B1/en active IP Right Grant
-
1998
- 1998-07-10 WO PCT/IB1998/001056 patent/WO1999003364A1/en not_active Application Discontinuation
- 1998-07-10 PL PL98338079A patent/PL338079A1/en unknown
- 1998-07-10 CA CA002296540A patent/CA2296540A1/en not_active Abandoned
- 1998-07-10 SK SK1819-99A patent/SK181999A3/en unknown
- 1998-07-10 HU HU0004526A patent/HUP0004526A3/en unknown
- 1998-07-10 AU AU79277/98A patent/AU727448B2/en not_active Ceased
- 1998-07-10 JP JP2000502680A patent/JP2001510026A/en active Pending
- 1998-07-10 CN CN98807193A patent/CN1263439A/en active Pending
- 1998-07-10 KR KR1020007000253A patent/KR20010021694A/en not_active Application Discontinuation
- 1998-07-10 EP EP98929576A patent/EP0999757A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU727448B2 (en) | 2000-12-14 |
| CN1263439A (en) | 2000-08-16 |
| ITRM970435A0 (en) | 1997-07-16 |
| HUP0004526A2 (en) | 2001-04-28 |
| CA2296540A1 (en) | 1999-01-28 |
| WO1999003364A1 (en) | 1999-01-28 |
| SK181999A3 (en) | 2000-10-09 |
| HUP0004526A3 (en) | 2001-11-28 |
| JP2001510026A (en) | 2001-07-31 |
| PL338079A1 (en) | 2000-09-25 |
| EP0999757A1 (en) | 2000-05-17 |
| ITRM970435A1 (en) | 1999-01-16 |
| IT1293539B1 (en) | 1999-03-01 |
| KR20010021694A (en) | 2001-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6831103B1 (en) | Composition comprising theanine | |
| US7674482B2 (en) | Method and compositions for potentiating pharmaceuticals with amino acid based medical foods | |
| KR100680121B1 (en) | Formulation containing lyso-phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals | |
| CA2344893C (en) | Combination of carnitines and resveratrol for prevention or treatment of cerebral and ageing disorders | |
| CN101248873A (en) | Drinking food product with sight protection function | |
| BRPI0617988A2 (en) | anti-obesity composition, use of melissa extract, use of a mixture of melissa extract and mori folium extract, use of a mixture of melissa extract, artemisia extract and mori folium extract and method to suppress obesity | |
| GB2596849A (en) | Nutritional supplement composition for treating coronavirus infections, cancer, ME, post viral & Chronic fatigue syndrome & neurodegeneration in an individual | |
| KR100481188B1 (en) | Use of Alkanoyl-L-Carnitine for the Treatment of Glutamate-Related Diseases | |
| KR102539374B1 (en) | Compositions for enhancing brain activity | |
| JP5275251B2 (en) | Composition comprising an extract of a combined herb for preventing and treating liver disease | |
| AU727448B2 (en) | Nutritional composition for subjects under stress | |
| US5482712A (en) | Galenic composition | |
| CN102836221A (en) | Composition containing Armillaria mellea and combination of one or several of Melissa, lavender, chrysanthemum and jasmine | |
| US20060269623A1 (en) | Herbal composition and method of use for promoting erections and treating erectile dysfunction in men | |
| JP2007500755A (en) | How to reduce symptoms of premenstrual syndrome | |
| US20030194453A1 (en) | Dietary supplement | |
| MXPA00000442A (en) | Nutritional composition for subjects under stress | |
| CN1119114A (en) | Seabuckthorn fruit flavone oral liquid and preparing process thereof | |
| KR20090024215A (en) | Means and method for enhancing a human sexual activity | |
| US20210353705A1 (en) | Method and composition for relieving fatigue and restoring energy | |
| CZ200088A3 (en) | Nutrition preparation for stress subjects | |
| JP2008031080A (en) | Lipid utilization-promoting composition | |
| CN114868924A (en) | Composition based on D-ribose and amino acid and application thereof | |
| CN101045138A (en) | Health-care product containing young bamboo powder for treating hypohemia and its preparing method | |
| BRPI1100167A2 (en) | antifatigue composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |